Clinical trials: Cancer Stem Cells
Prostate Cancer, Erectile Dysfunction
Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction
Erectile dysfunction is a frequent adverse event after radical prostatectomy for prostate cancer. It is the consequence of penile vascular damage, mainly arterial insufficiency and venous leakage associated with fibrosis of the…
- Trial name
- INSTIN (NCT01089387)
- Testing
- injection of bone marrow mononucleated cells
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Sickle Cell Disease, Chronic Kidney Diseases
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
The purpose of this study is to test the efficacy of a peer support coaching intervention to improve activated chronic illness self-management versus an attention control group in 225 adolescents and young adults with childhood…
- Conditions
- Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer
- Trial name
- PiCASO (NCT03938324)
- Testing
- PiCASO Intervention Group
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Duke University
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Non Hematologic Cancers, Metastatic Cancer
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
This is a Phase I, open-label, multicenter, dose-escalation trial of VS-4718, a focal adhesion kinase inhibitor, in subjects with metastatic non-hematologic malignancies.
- Trial name
- NCT01849744
- Testing
- VS-4718
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Verastem, Inc.
Breast Cancer
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- CTC (NCT00005798)
- Testing
- Carboplatin, Cyclophosphamide, Thiotepa
- Where
- 3 sites in United States
- Volunteers
- 209 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by…
- Trial name
- CARTITUDE-5 (NCT04923893)
- Testing
- Bortezomib, Dexamethasone, Lenalidomide
- Where
- 136 sites in United States, Argentina and 24 more
- Volunteers
- 743 people
- Sponsor
- Janssen Research & Development, LLC
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
This study will examine the safety of clofarabine, TLI and ATG as a reduced conditioning regimen prior to allogeneic transplantation.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT00697684
- Testing
- Antithymocyte Globulin, Clofarabine
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Beth Israel Deaconess Medical Center
Viral Infection
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
The subjects eligible for this trial have a type of blood cell cancer, other blood disease or a genetic disease for which they will receive a stem cell transplant.
- Trial name
- ARMS (NCT01570283)
- Testing
- Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- AlloVir
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT02037256
- Testing
- bortezomib, filgrastim, autologous hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Graft Versus Host Disease, Hematopoietic/Lymphoid Cancer
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
This pilot clinical trial studies donor stem cell transplant followed by cyclophosphamide in treating patients with hematological diseases.
- Trial name
- NCT02248597
- Testing
- fludarabine phosphate, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Wake Forest University Health Sciences
MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)
Haplo-Cord HSCT for AML/MDS
This study aims to investigate the clinical efficacy of haploidentical-cord blood hematopoietic stem cell transplantation in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), and to analyze…
- Trial name
- NCT07588360
- Testing
- haplo-cord HSCT, Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX)
- Where
- 4 sites in China
- Volunteers
- 82 people
- Sponsor
- Fujian Medical University Union Hospital
Lymphoma
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give…
- Trial name
- NCT00006373
- Testing
- etoposide, ifosfamide, topotecan hydrochloride
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
The purpose of this study is to determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of participants achieving stringent complete response (sCR), as defined by the…
- Trial name
- NCT02874742
- Testing
- Lenalidomide, Bortezomib, Dexamethasone
- Where
- 36 sites in United States
- Volunteers
- 224 people
- Sponsor
- Janssen Research & Development, LLC
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
This phase II trial studies how well ibrutinib works in preventing acute leukemia in patients after reduced-intensity conditioning and stem cell transplant.
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT03267186
- Testing
- Ibrutinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Andrew Rezvani
Acute Myeloid Leukemia (AML)
Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML
1. To evaluate whether stem cell transplantation from a matched sibling donor is equivalent to a matched unrelated donor in in a second complete remission of acute myeloid leukemia (AML). 2.
- Trial name
- NCT00606723
- Testing
- Hematopoietic stem cells from bone marrow or peripheral blood
- Where
- 24 sites in Austria, Czechia and 1 more
- Volunteers
- 154 people
- Sponsor
- Hannover Medical School
Neuroepithelial Tumor, Solid Tumor
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
There is currently no standard treatment for patients with neuro-epithelial (brain) or other solid tumors in another part of the body who do not have adequate suitable autologous hematopoietic progenitor cells available and/or…
- Conditions
- Neuroepithelial Tumor, Solid Tumor, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT02653196
- Testing
- Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy, Keratinocyte Growth Factor, Alemtuzumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Montefiore Medical Center
Lymphoma
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Giving high doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00521261
- Testing
- anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Hematological Malignancies
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
In this study, participants with high-risk hematologic malignancies undergoing hematopoietic cell transplantation (HCT), who do not have a suitable human leukocyte antigen (HLA)-matched related/sibling donor (MSD), matched…
- Trial name
- NCT02199041
- Testing
- Cyclophosphamide, Thiotepa, Fludarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Steroid-Refractory Acute Graft Versus Host Disease
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
This is an open-label, randomized, Phase 3, multicenter trial, which has been designed to compare the efficacy and safety of T-Guard to ruxolitinib in patients with Grade III or IV Steroid-Refractory acute Graft-Versus-Host…
- Trial name
- 2002 (NCT04934670)
- Testing
- T-Guard, Ruxolitinib
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 12 people
- Sponsor
- Xenikos
CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
This phase I trial studies the side effects and best dose of ribociclib and everolimus and to see how well they work in treating patients with malignant brain tumors that have come back or do not respond to treatment.
- Conditions
- CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Childhood Ependymoma
- Trial name
- NCT03387020
- Testing
- Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 12 sites in United States
- Volunteers
- 22 people
- Sponsor
- Pediatric Brain Tumor Consortium
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.